SCHEMBL3436679

SCHEMBL3436679

Cn1cc2ccc(CO)cc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
KDM4E B2RXH2 2/20 0.56
NSD2 O96028 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HSD17B10 Q99714 1/20 0.44
KDM4C Q9H3R0 2/20 0.43
NOTUM Q6P988 1/20 0.40
MAT2A P31153 1/20 0.36
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
RPS6KA5 O75582 1/20 0.35
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
SLC5A2 P31639 1/20 0.34
CA12 O43570 1/20 0.34
CA2 P00918 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30570094 0.86 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1HSD17B10
SCHEMBL3436381 0.86 KDM4E (0.49) MAPTKDM4ENSD2ALDH1A1HSD17B10
SCHEMBL12729869 0.84 KDM4E (0.58) MAPTKDM4ENSD2ALDH1A1HSD17B10
SCHEMBL904782 0.82 MAPT (0.61) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL18339237 0.82 MAPT (0.56) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL24664403 0.79 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL3436681 0.79 NOTUM (0.42) MAPTKDM4ENSD2ALDH1A1HSD17B10
SCHEMBL30570132 0.79 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1KDM4C
SCHEMBL24338409 0.79 IRAK4 (0.43) MAPTKDM4ENSD2ALDH1A1HSD17B10
SCHEMBL30007444 0.79 MAPT (0.53) MAPTKDM4ENSD2ALDH1A1KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731262-A1 PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND Astellas Pharma Inc. (JP) 2026-04-29 EP disclosed
EP-4559906-A1 HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN Astellas Pharma Inc. (JP) 2025-05-28 EP disclosed
US-20250145631-A1 HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN ASTELLAS PHARMA INC. (JP) 2025-05-08 US disclosed
WO-2024261257-A1 PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2024-12-26 WO disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 CN disclosed
WO-2024019103-A1 HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN アステラス製薬株式会社 2024-01-25 WO disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 CN disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 WO disclosed
EP-3763367-A1 PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-01-13 EP disclosed
EP-3763367-A1 PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2021-01-13 EP disclosed
US-8987461-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-03-24 US disclosed
US-20140194469-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-07-10 US disclosed
US-20140194469-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-07-10 US disclosed
US-20140194469-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-07-10 US disclosed
WO-2014089364-A1 HISTONE DEMETHYLASE INHIBITORS QUANTICEL PHARMACEUTICALS, INC (US) 2014-06-12 WO disclosed
WO-2014089364-A1 HISTONE DEMETHYLASE INHIBITORS QUANTICEL PHARMACEUTICALS, INC (US) 2014-06-12 WO disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145631-A1 HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN KRAS, NRAS, HRAS MAPT 4351/4885KDM4E 3766/4885NSD2 406/4885
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI MAPT 4033/4885KDM4E 1069/4885NSD2 2255/4885
US-20140194469-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A MAPT 2204/4885KDM4E 19/4885NSD2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.